We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eyelid Closure in Glaucoma Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00832832
First Posted: January 30, 2009
Last Update Posted: September 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Henry D. Jampel, M.D., M.H.S., Johns Hopkins University
  Purpose
This research is being done to determine if closing your eyelids after you take your glaucoma drops makes them more effective in lowering your eye pressure, and to determine if closing your eyelids for 5 minutes is better than closing them for one minute

Condition Intervention
Glaucoma Other: Eyelid closure Other: No intervention will be assigned

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Eyelid Closure in Topical Glaucoma Therapy

Resource links provided by NLM:


Further study details as provided by Henry D. Jampel, M.D., M.H.S., Johns Hopkins University:

Primary Outcome Measures:
  • Amount of intraocular pressure lowering [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Amount of intraocular pressure lowering [ Time Frame: 1 hour and one week ]

Enrollment: 60
Study Start Date: January 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eyelid closure
Eyelids will be closed after administration of eye drop
Other: Eyelid closure
Eyelid will be closed after eye drop instillation
Active Comparator: No eyelid closure
Eyelids will not be closed after eye drop instillation
Other: No intervention will be assigned
No intervention will be assigned to this arm
Other Name: No intervention needed in Arm 2

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 18 years, use of one of the three topical prostaglandins (latanoprost, travaprost, or bimatoprost), and no other IOP-lowering eye drops for at least one month.

Exclusion Criteria:

  • Previous laser or incisional surgery for glaucoma, use of punctual plugs, an abnormal slit lamp exam (except for cataract or intraocular lens implant) and incisional eye surgery within the last 6 months.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00832832


Locations
United States, Maryland
Johns Hopkins - The Wilmer Eye Institute
Baltimore, Maryland, United States, 21009
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Henry D Jampel, MD Johns Hopkins University
  More Information

Responsible Party: Henry D. Jampel, M.D., M.H.S., Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00832832     History of Changes
Other Study ID Numbers: NA_00021272
First Submitted: January 29, 2009
First Posted: January 30, 2009
Last Update Posted: September 20, 2012
Last Verified: September 2012

Keywords provided by Henry D. Jampel, M.D., M.H.S., Johns Hopkins University:
Glaucoma
Eye drop
Intraocular pressure
Eyelid closure

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Tetrahydrozoline
Pharmaceutical Solutions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents